CA2503715A1 - Kinase inhibitors - Google Patents
Kinase inhibitors Download PDFInfo
- Publication number
- CA2503715A1 CA2503715A1 CA002503715A CA2503715A CA2503715A1 CA 2503715 A1 CA2503715 A1 CA 2503715A1 CA 002503715 A CA002503715 A CA 002503715A CA 2503715 A CA2503715 A CA 2503715A CA 2503715 A1 CA2503715 A1 CA 2503715A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- compound
- carbonitrile
- thiazole
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42231302P | 2002-10-30 | 2002-10-30 | |
US60/422,313 | 2002-10-30 | ||
PCT/US2003/034100 WO2004041164A2 (en) | 2002-10-30 | 2003-10-24 | Kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2503715A1 true CA2503715A1 (en) | 2004-05-21 |
Family
ID=32312490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002503715A Abandoned CA2503715A1 (en) | 2002-10-30 | 2003-10-24 | Kinase inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1558609A4 (de) |
JP (1) | JP2006507302A (de) |
AU (1) | AU2003285007A1 (de) |
CA (1) | CA2503715A1 (de) |
WO (1) | WO2004041164A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA011009B1 (ru) | 2003-01-14 | 2008-12-30 | Арена Фармасьютикалз Инк. | 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
EP1756084B1 (de) * | 2004-06-04 | 2008-11-26 | Arena Pharmaceuticals, Inc. | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ, インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
WO2006117608A1 (en) | 2005-04-29 | 2006-11-09 | Ferring International Center S.A. | Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
JP2009521461A (ja) * | 2005-12-22 | 2009-06-04 | アイカジェン, インコーポレイテッド | カルシウムチャネルアンタゴニスト |
ATE539748T1 (de) * | 2006-01-27 | 2012-01-15 | Array Biopharma Inc | Glucokinaseaktivatoren |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
EA016679B1 (ru) | 2007-04-18 | 2012-06-29 | Пфайзер Продактс Инк. | Сульфониламидные производные для лечения аномального роста клеток |
WO2008129080A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
NZ583538A (en) | 2007-09-21 | 2012-06-29 | Array Biopharma Inc | Pyridin-2-yl-amino-1,2,4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
EP2571867B1 (de) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Neuartige pyrimidinderivate |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2688883B1 (de) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidinderivate |
WO2012149528A1 (en) * | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
TWI620748B (zh) * | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
TWI667236B (zh) * | 2017-06-13 | 2019-08-01 | 財團法人國家衛生研究院 | 作為蛋白激酶抑制劑的胺基噻唑化合物 |
CN111116575B (zh) * | 2019-12-18 | 2021-06-15 | 浙江工业大学 | 一种5-氟-2,4-嘧啶二胺类化合物及其制备与应用 |
CN111388656B (zh) * | 2020-04-17 | 2021-01-15 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | Kallistatin蛋白在制备防治OHSS的药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0009721B8 (pt) * | 1999-04-15 | 2021-11-23 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteína cíclica |
US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
EP1347971B1 (de) * | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie |
-
2003
- 2003-10-24 CA CA002503715A patent/CA2503715A1/en not_active Abandoned
- 2003-10-24 WO PCT/US2003/034100 patent/WO2004041164A2/en active Application Filing
- 2003-10-24 JP JP2004550143A patent/JP2006507302A/ja not_active Withdrawn
- 2003-10-24 EP EP03779322A patent/EP1558609A4/de not_active Withdrawn
- 2003-10-24 AU AU2003285007A patent/AU2003285007A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004041164A3 (en) | 2004-10-07 |
EP1558609A2 (de) | 2005-08-03 |
AU2003285007A1 (en) | 2004-06-07 |
EP1558609A4 (de) | 2008-05-28 |
JP2006507302A (ja) | 2006-03-02 |
WO2004041164A2 (en) | 2004-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7115597B2 (en) | Tyrosine kinase inhibitors | |
EP1503757B1 (de) | Tyrosinkinase-hemmer | |
US6958340B2 (en) | Tyrosine kinase inhibitors | |
EP1259235B1 (de) | Tyrosinkinase inhibitoren | |
EP1218376B1 (de) | Tyrosin kinase inhibitoren | |
CA2503715A1 (en) | Kinase inhibitors | |
EP1226119B1 (de) | Tyrosin kinase inhibitoren | |
EP1226136B1 (de) | Tyrosin kinaseinhibitoren | |
US6927293B2 (en) | Tyrosine kinase inhibitors | |
US7265134B2 (en) | Tyrosine kinase inhibitors | |
US20040171630A1 (en) | Tyrosine kinase inhibitors | |
US20050070546A1 (en) | Tyrosine kinase inhibitors | |
US20040235875A1 (en) | Tyrosine kinase inhibitors | |
US20040220216A1 (en) | Tyrosine kinase inhibitors | |
WO2003024931A1 (en) | Tyrosine kinase inhibitors | |
EP1259236A1 (de) | Tyrosinkinase-inhibitoren | |
WO2003011838A1 (en) | Tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |